Genomic drug developer Tessera Therapeutics raised $230m in a round co-led by SoftBank Vision Fund 2 as it works on its gene writing technology.

Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.

LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.

Lilly Asia Ventures has led a $23.2m round for the digital diagnostics technology developer, investing alongside new and existing backers.

Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

Cambrian Biopharma returned to back the immunotherapy developer's series B round, following its series A three months ago.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.

Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.

The brain disease treatment developer was founded in 2019 on the back of more than a decade’s collaborative research from MIT and Harvard.